Solstice Closes $18M Series A; Raises Stakes in RNAi Delivery
By Jennifer Boggs
Friday, January 4, 2013
The promise of RNAi the idea that specific genes can be pinpointed and silenced to treat disease has loomed large on biopharma's radar for the past decade, even netting a 2006 Nobel to RNAi discoverers Craig Mello and Andrew Fire.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5476
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.